Drug discovery with a strong track record

Exceptional capabilities in medicinal chemistry and translational science are the foundation of Redx. We have built an attractive portfolio of assets and have a strong track record of drug discovery. Our drug discovery engine has delivered five molecules to clinical stage development, and we have completed a number of major partnering transactions in recent years. Our portfolio includes two Phase 2 assets; RXC004, a Porcupine inhibitor targeting Wnt-ligand dependent tumours and RXC007, a selective ROCK2 inhibitor for the treatment of interstitial lung diseases including idiopathic pulmonary fibrosis, as well as a pipeline of rapidly advancing research programs and collaborations, driven by our world-class drug discovery engine.